...
首页> 外文期刊>International Journal of Pharmaceutics >Inner ear biocompatibility of lipid nanocapsules after round window membrane application.
【24h】

Inner ear biocompatibility of lipid nanocapsules after round window membrane application.

机译:圆窗膜应用后脂质纳米胶囊的内耳生物相容性。

获取原文
获取原文并翻译 | 示例

摘要

Nanoparticle-mediated drug delivery represents the future in terms of treating inner ear diseases. Lipid core nanocapsules (LNCs), 50 nm in size, were shown to pass though the round window membrane (RWM) and reached the spiral ganglion cells and nerve fibers, among other cell types in the inner ear. The present study aimed to evaluate the toxicity of the LNCs in vitro and in vivo, utilizing intact round window membrane delivery in rats. The primary cochlear cells and mouse fibroblast cells treated with LNCs displayed dosage dependant toxicity. In vivo study showed that administration of LNCs did not cause hearing loss, nanoparticle application-related cell death, or morphological changes in the inner ear, at up to 28 days of observation. The cochlear neural elements, such as synaptophysin, ribbon synapses, and S-100, were not affected by the administration of LNCs. However, expression of neurofilament-200 decreased in SGCs and in cochlear nerve in osseous spiral lamina canal after LNC delivery, a phenomenon that requires further investigation. LNCs are potential vectors for the delivery of drugs to the inner ear.
机译:纳米粒子介导的药物递送代表了治疗内耳疾病的未来。大小为50 nm的脂质核心纳米胶囊(LNC)已通过圆窗膜(RWM)到达并到达了螺旋神经节细胞和神经纤维以及内耳中的其他细胞类型。本研究旨在利用完整的圆窗膜在大鼠体内评估LNC在体外和体内的毒性。用LNC处理的原代耳蜗细胞和小鼠成纤维细胞显示出剂量依赖性毒性。体内研究表明,在长达28天的观察中,服用LNC不会引起听力损失,与纳米颗粒应用相关的细胞死亡或内耳形态变化。耳蜗神经元,如突触素,带状突触和S-100,不受LNC给药的影响。然而,LNC递送后,在SGCs和骨螺旋椎管中的耳蜗神经中neurofilament-200的表达下降,这一现象需要进一步研究。 LNC是将药物输送到内耳的潜在载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号